Archive · 18 Nov 2025
Novo Nordisk Slashes Wegovy Price, Plans Oral Pill Launch in US
Danish drugmaker Novo Nordisk is making Wegovy, its obesity drug, cheaper in the US and will soon launch an oral version to attract more patients and compete with rivals.
The company is also adjusting its business strategy to better suit consumer behavior in the weight-loss market.
Novo Nordisk to lower price of injectable Wegovy in the US to $349 per month for cash-paying patients
Company plans to launch oral version of Wegovy in the US by the end of the year
Novo Nordisk aims to expand patient access and regain market share with the oral pill
First-time doses of Wegovy and Ozempic to be available for $149 per month through TrumpRx platform or commercial partners
CEO Mike Doustdar acknowledges slowed sales growth and need for a more aggressive strategy in the US
- Who
- Novo Nordisk
- What
- Lowered price of Wegovy and plans to launch oral version in the US
- When
- November 17, 2022; oral pill launch expected by end of 2022
- Where
- United States
- Why
- To expand patient access, regain market share, and adapt to consumer behavior
Novo Nordisk's Optimistic View
Analysts' Cautious Stance
Pricing and Accessibility
Novo Nordisk's Optimistic View
Novo Nordisk believes lower prices will significantly expand patient access to Wegovy
Analysts' Cautious Stance
Analysts question whether price cuts will lead to sufficient volume offset
- Expected launch date of oral Wegovy
- End of 2022
- Sales growth in Q1 2022
- 18%
- Expected sales growth in Q4 2022
- 4% decrease
